CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Ono Pharmaceutical Co. Ltd
I-Mab Biopharma US Limited
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Neonc Technologies, Inc.
Centre Leon Berard
I-Mab Biopharma US Limited
AstraZeneca
Aulos Bioscience, Inc.
Pfizer
Genentech, Inc.
ImmunityBio, Inc.
Mayo Clinic
Suzhou Transcenta Therapeutics Co., Ltd.
Amgen
University of Pittsburgh
Amgen
Bristol-Myers Squibb
BicycleTx Limited
Vedanta Biosciences, Inc.
Astellas Pharma Inc
GERCOR - Multidisciplinary Oncology Cooperative Group
Bolt Biotherapeutics, Inc.
Incyte Corporation
Bristol-Myers Squibb
Toray Industries, Inc
Jiangsu Cancer Institute & Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb
Fukushima Medical University
Ono Pharmaceutical Co. Ltd
National University Hospital, Singapore
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
University Hospital, Essen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kidney Cancer Research Bureau
CNBG-Virogin Biotech (Shanghai) Ltd.
Fate Therapeutics
Nektar Therapeutics
University of Kansas Medical Center
Incyte Corporation
Yonsei University
AIO-Studien-gGmbH
Chinese PLA General Hospital
ExcellaBio LLC
Shanghai Zhongshan Hospital
MultiVir, Inc.
Bristol-Myers Squibb